Brief: Mannkind Receives U.S. FDA Fast Track Designation For Clofazimine Inhalation Suspension For The Treatment Of Nontuberculous Mycobacterial Lung Disease
06/05/2024 11:18
May 6 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR
CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF
NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG DISEASE
* MANNKIND CORP: SINGLE REGISTRATIONAL STUDY ANTICIPATES
GETTING
UNDERWAY IN JUNE 2024 IN U.S., AND INTERNATIONALLY IN SECOND
HALF OF 2024
Source text for Eikon: ID:nGNX4CBzPs
Further company coverage: MNKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children